tirzepatide weight loss program michigan STL Medical Tirzepatide for Medical Weight Loss

This impressive performance led to its FDA approval on May 13, 2022, as a treatment for type 2 diabetes

Acknowledgements Editorial support was provided by Richard Ogilvy-Stewart of Apollo, OPEN Health Communications, and funded by Novo Nordisk A/S, in accordance with Good Publication Practice guidelines (www.ismpp.org/gpp-2022)

The SURMOUNT-5 trial showed tirzepatide produced 20.2% weight reduction versus 13.7% with semaglutide at 72 weeks a 47% greater relative weight loss

Some users even report increased energy as reduced caloric intake paradoxically frees up metabolic resources that were previously devoted to processing excess food